David Hung, Nuvation Bio CEO
August 5, 2024 03:35 PM EDT
R&D

Nu­va­tion paus­es BET in­hibitor plans af­ter check­ing out in­ter­im Phase 1 da­ta

Max Bayer

Pharma Reporter

Nu­va­tion Bio won’t take its can­cer drug NUV-868 in­to a Phase 2 tri­al for now, fol­low­ing a look at in­ter­im safe­ty and ef­fi­ca­cy da­ta from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mer­ck, Dai­ichi Sankyo de­tail Phase 2 ADC re­sults in small cell lung can­cer, bis­pe­cif­ic com­bo strat­e­gy

In­vestors pour $370M+ in­to Ken Song's au­toim­mune biotech af­ter his Rayze­Bio suc­cess

Sum­mit's Phase 3 da­ta back up biotech's boasts of beat­ing Keytru­da in lung can­cer

Terns’ oral GLP-1 pass­es Phase 1 test with promis­ing weight loss af­ter one month

Re­lay Ther­a­peu­tics re­ports pos­i­tive PFS da­ta for its PI3Kα in­hibitor com­bo in breast can­cer

Eli Lil­ly in­vests in Su­per­lu­mi­nal's $120M Se­ries A round as AI-fo­cused star­tups eye the clin­ic

A service from the Financial Times